RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Akkurat i dette øyeblikk blei fase 2-resultatene til Oxford/AstraZeneca-vaksinen publisert. Helt sinnssykt at man har fått til dette på 3/4 år. Håper norske fagfolk både i og utenfor myndighetsapparatet leser dette veldig grundig. https://t.co/UaVgM2oXKS
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/QgN7ungbUt
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @JSS779: More good vaccine news...
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Authors note that their new findings could be encouraging if the immune responses found in their study are associated with protection against infection with SARS-CoV-2, but this study did not assess efficacy and phase 3 trials are ongoing to confirm this h
More good vaccine news...
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
🚨💉 ¡YA! La VACUNA de Oxford-AstraZeneca también funciona. Por fin ha salido en The Lancet el artículo que esperábamos: demostrada eficacia en personas mayores de 70 años. Y más. Te lo contamos ahora en @COPE https://t.co/CB1XJTpjen
Our latest data from @JennerInstitute and @OxfordVacGroup in showing that the Oxford/AZ #COVID19 #vaccine is safe and immunogenic in older adults-the highest risk groups. Another important step on the path, but the hard work continues!
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we have got to this point in <12 months. Unbelievable levels of global collaboration. https://t.co/K46JRbzxwv
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
@FredStalhake Ah det som publicerades var vist inte effektiviteten nej https://t.co/63aBhSoEd9
The Oxford #COVID19 💉 shows a strong immune response in adults in their 60s and 70s, raising hopes that it can protect age groups most at risk from the virus. Further assessment of the efficacy of this 💉 is warranted in all age groups with comorbidities. h
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/6rA6d5Gouz
RT @CrisBonorino: More good news https://t.co/3rkESuF7eF
Vacuna de Oxford. Más lenta pero más segura según publica hoy The Lancet. En @EsquireEs hemos visitado sus instalaciones y hablamos con los autores de la investigación https://t.co/9y1Sfezt7w https://t.co/PxZDkAFmI6
I woke up to an email from the Oxford Vaccine Centre Team. Phase 2 findings: https://t.co/sncIX7YqOV
RT @tom_watson: Another uplifting tweet.
RT @CrisBonorino: More good news https://t.co/3rkESuF7eF
More good news
RT @stuartjdneil: More positive news. ChadOx1 is better tolerated and induces similar levels of immune responses to CoV2 Spike in the elder…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @angel_h_merino: Primeros datos de #vacunas del covid de estudio fase 2/3 #ChAdOx1 #AZD1222 en @TheLancet
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Promising news from the Oxford/AstraZeneca vaccine about its efficacy in older adults https://t.co/7jH8UaDY88
RT @sherezade_mr: Otra vacuna (UK) en jóvenes y mayores. Ensayo clínico de fase 2. Link al artículo científico en la noticia, de los que ti…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
ChAdOx1 nCoV-19 https://t.co/BlWr30qkpG https://t.co/ihR14OZrzX
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
More positive news. ChadOx1 is better tolerated and induces similar levels of immune responses to CoV2 Spike in the elderly. Fingers crossed for the efficacy data in the next couple of weeks. https://t.co/m3NujT37so
RT @paulwaugh: More good news for everyone to wake up to. https://t.co/VmNpWJTb4F
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
A light...
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @MOFoodSci: "ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across…
Our latest paper on the @UniofOxford @JennerInstitute #COVID19 vaccine. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial h
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/SbLnUHNhpK
Data published today in The Lancet suggest that a robust immune response is triggered by the ChAdOx1 nCoV-19 vaccine in healthy adults over the age of 56. Full publication: https://t.co/3GE07meg67
RT @JonathanKBall: Interest today from @sarahjulianotts on @BBCNottingham about Oxford vaccine generating good immunity in elderly people.…
[Articles] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/zPjYu4QxoF
Interest today from @sarahjulianotts on @BBCNottingham about Oxford vaccine generating good immunity in elderly people. For those who wish to delve more, here’s the phase 2 data: https://t.co/MXKk0MYPAt
The Lancet: "Seguridad e inmunogenicidad de la vacuna ChAdOx1 nCoV-19 administrada en un régimen de refuerzo primario en adultos jóvenes y ancianos (COV002): un ensayo simple ciego, aleatorizado, controlado, de fase 2/3" https://t.co/ovhOMBdG7z
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Lisää hyviä rokoteuutisia. AstraZenacan ja Oxfordin yliopiston covid-19-rokote näyttäisi toimivan turvallisesti kaikenikäisille. https://t.co/bPopCRGCIU
Promising
RT @DrDerekConnolly: The results of the Oxford Jenner Institute COVID Vaccine are stunning ⭐️ ChAdOx1 nCoV-19 appears to be better tolerat…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - Brits do it the right way, results published in a peer reviewed journal
Some good news https://t.co/0kINeslKBD
💉💉Oxford #COVID19 vaccine one step closer! 🤞🏼🤞🏼
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @angel_h_merino: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV…
Further promising results for the ChAdOx1 nCoV-19 vaccine with similar immunogenicity across all age groups. https://t.co/O3G5fG6vgN
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/yXDHdvGfQG
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Otra vacuna (UK) en jóvenes y mayores. Ensayo clínico de fase 2. Link al artículo científico en la noticia, de los que tienen datos 😁
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @tom_watson: Another uplifting tweet.
RT @tom_watson: Another uplifting tweet.
RT @tom_watson: Another uplifting tweet.
RT @tom_watson: Another uplifting tweet.
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @paulwaugh: More good news for everyone to wake up to. https://t.co/VmNpWJTb4F
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/nLTdF0aOyD
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @VishnuNDTV: Huge development for India.